Regeneron Pharmaceuticals, Inc. (0R2M.L)
| Chiusura precedente | 742,32 |
| Aperto | 0,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 830,296M |
| Beta (5 anni mensile) | 0,24 |
| Rapporto PE (ttm) | 0,11 |
| EPS (ttm) | 70,31 |
| Prossima data utili | 03 feb 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission; patients also significantly improved their ability to swallow compared to placebo Dupixent is now an option for the approximately 50,000 adults and adolescents living with severe uncontrolled eosinophilic esophagitis in the European Union (EU) Dupixent now approved to treat five diseases with underlying type 2 inflammation in the EU TARRYTOWN,
- GlobeNewswire
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of life In Europe, about 80,000 children aged 6 months to 5 years with uncontrolled severe atopic dermatitis are candidates for systemic therapy TARRYTOWN, N.Y. and PARIS, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Rege
- GlobeNewswire
Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition
Nation’s Most Innovative Teens will Showcase Research with Prizes of Over $1.8 millionTARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year’s Regeneron Science Talent Search, the nation’s oldest and most prestigious science and math competition for high school seniors. The competition, now in its 82nd year, celebrates and rewards young scientist
